Skip to main content
TipRanks
Go Ultimate75% OFF

Haemonetics (HAE) Net Revenue by Segment

451 Followers

Net Revenue by Segment

Haemonetics reported net revenue by segment of $357.76M in Q2 FY2027, up 5.4% from Q1 FY2027 and up 9.3% year over year. This is the highest value since 2021.

Tracks sales across product and service lines, showing which offerings—such as devices, consumables, and service contracts—are driving growth. For Haemonetics, a rising share of consumables or recurring service revenue points to steadier, more predictable cash flow tied to an installed base, while reliance on one-time equipment sales can make top-line performance more cyclical.

-$100.00M$0.00$100.00M$200.00M$300.00MJun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Recent quarter shows a dramatic Apheresis jump that aligns with management’s Apheresis disclosure—part real growth from Persona PLUS rollout and part reporting/reclassification, so treat it as both product momentum and a structural change. MedSurg exhibits sustained, multi‑quarter strength and supports upgraded guidance, while Plasma is steady but management remains cautious on volumes. Blood Center and Other have slumped—timing and working‑capital boosts inflated cash; watch margin pressure and OEM/IVT softness for downside risk.

HAE Net Revenue by Segment

PeriodOtherPlasmaBlood CenterApheresisMedsurgTotal
Q2 FY2027Sep 30, 2026$0.00$0.00$0.00$204.81M$152.95M$357.76M
Q1 FY2027Jun 30, 2026$0.00$0.00$0.00$191.32M$148.06M$339.38M
Q4 FY2026Mar 31, 2026$0.00$130.30M$56.40M$0.00$159.60M$346.30M
Q3 FY2026Dec 31, 2025$0.00$138.91M$56.56M$0.00$143.50M$338.97M
Q2 FY2026Sep 30, 2025$0.00$125.36M$56.45M$0.00$145.50M$327.31M
Q1 FY2026Jun 30, 2025$0.00$129.90M$51.84M$0.00$139.66M$321.39M
Q4 FY2025Mar 31, 2025$0.00$126.74M$56.01M$0.00$147.86M$330.60M
Q3 FY2025Dec 31, 2024$0.00$134.22M$70.34M$0.00$143.97M$348.54M
Q2 FY2025Sep 30, 2024$0.00$138.56M$68.53M$0.00$138.42M$345.51M
Q1 FY2025Jun 30, 2024$0.00$135.91M$66.25M$0.00$134.02M$336.17M
Q4 FY2024Mar 31, 2024$4.42M$138.45M$71.13M$0.00$129.29M$343.29M
Q3 FY2024Dec 31, 2023$4.12M$146.72M$71.61M$0.00$113.79M$336.25M
Q2 FY2024Sep 30, 2023$4.17M$141.75M$68.91M$0.00$103.36M$318.18M
Q1 FY2024Jun 30, 2023$6.01M$138.48M$67.31M$0.00$99.54M$311.33M
Q4 FY2023Mar 31, 2023-$453.00K$131.99M$70.31M$0.00$102.57M$304.42M
Q3 FY2023Dec 31, 2022-$1.99M$136.57M$76.83M$0.00$93.89M$305.30M
Q2 FY2023Sep 30, 2022$383.00K$128.89M$75.65M$0.00$92.56M$297.49M
Q1 FY2023Jun 30, 2022$2.66M$103.04M$66.57M$0.00$89.18M$261.46M
Q4 FY2022Mar 31, 2022$4.57M$101.45M$73.02M$0.00$85.97M$265.00M
Q3 FY2022Dec 31, 2021$6.45M$96.69M$74.53M$0.00$82.10M$259.77M
Q2 FY2022Sep 30, 2021$6.73M$82.00M$75.26M$0.00$75.90M$239.90M
Q1 FY2022Jun 30, 2021$7.38M$71.80M$71.74M$0.00$77.61M$228.53M

Related KPIs